Bronchodilators form the foundation of symptomatic treatment of COPD. Several long-acting
bronchodilators are now available for use in COPD, but publications of large-scale studies of …

Long-acting beta2-agonists (LABAs) are recommended in the management of patients with
chronic obstructive pulmonary disease (COPD). Previous studies have demonstrated that …

Background: Combined treatment with inhaled corticosteroids and long acting β2 agonists is
approved for the treatment of chronic obstructive pulmonary disease (COPD), but little is …

Formoterol fumarate is a β2-agonist bronchodilator that combines a fast onset of action with
a long duration of action. Its fast onset of action is well documented in asthma but has not …

Study objectives: To compare the efficacy of adding formoterol or salbutamol to regular
ipratropium bromide treatment in COPD patients whose conditions were suboptimally …

OBJECTIVES: To compare the onset and magnitude of bronchodilation after dry powder
inhalations of formoterol fumarate (Foradil Aerolizer) versus salmeterol xinofoate (Serevent …

Background and objectives: Data on the onset of action of COPD medications are lacking.
This study compared the onset of bronchodilation following different inhaled therapies in …

The effects of the long-acting β2-agonist formoterol, the anticholinergic drug oxitropium
bromide, and their combination were compared in 16 patients with partially reversible stable …

We studied 16 patients with stable COPD in a double blind, double dummy, placebo-
controlled, within patient study to see if formoterol could be used as a rescue drug. We …

The aim of this pilot study was to explore the relative efficacy in terms of improvement in
symptoms and lung function of combining fluticasone propionate/salmeterol combination …